G1 Therapeutics Inc. (GTHX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of G1 Pharma (GTHX)

G1 Therapeutics, Inc. (GTHX) is developing anti-cancer treatments while operating within a strict US legal framework, which eliminates external political risks. Management is focused on increasing sales and identifying new applications for its bone marrow protection drug. The share price retrospective at the level highlights financial challenges: a liquidity deficit and the slow adoption dynamics of Cosela.

GTHX G1 Therapeutics: Enterprise Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/15/2026

GTHX (G1 Therapeutics Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
Summary company analytics:GTHX (G1 Pharma)
Original product of G1 Therapeutics

The G1 Therapeutics, Inc. (GTHX) model minimizes capital expenditures by outsourcing production to third-party contractors. This indicator compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, determining the real value of assets relative to their yield. By analyzing the company's EV/EBITDA multiple over time, an investor separates market noise from fundamental stability and assesses the efficiency of debt load management.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences, Inc CHRS|Corbus Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc.|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Lixte Biotechnology Holdings LIXT|Enterprise Value to EBITDA Ratio CTXR|Company Value to EBITDA Cellectar Biosciences CLRB|Enterprise Value to EBITDA Ratio BLRX (BioLineRx Ltd.)|CANF (Can-Fite BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|Aprea Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KZIA (Kazia)|Silexion Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NCNA (nucana.com)|CMRX: EV/EBITDA Multiple|Company Value to EBITDA cyclacel.com (CYCC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)